BALTIMORE, March 24, 2022–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that Dr. Adam Kaplin, Chief Scientific Officer, will appear as a featured guest on the Cheddar News Network show "Cheddar Innovates" on Thursday, March 24th, 2022 at 11:50am ET.
The appearance will be streamed online via Cheddar News.
Dr. Kaplin will discuss the business of aging and the Company's Phase 2 clinical trial of lead candidate MYMD-1 as a therapy for delaying aging and expanding health lifespan. He will address the future of this projected $600 billion market and what the next steps for MyMD will be towards bringing a drug to market.
"Cheddar Innovates," hosted by Alicia Nieves and Azia Celestino, is a weekly show focused on the latest and greatest in history, technology, science, and nature.
A replay of the appearance will be provided on the MyMD website when available after its conclusion.
About MyMD Pharmaceuticals, Inc.
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical-stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit www.mymd.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and none of MyMD nor its affiliates assume any duty to update forward-looking statements. Words such as "anticipate," "believe," "could," "estimate," "expect," "may," "plan," "will," "would'' and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the timing of, and MyMD’s ability to, obtain and maintain regulatory approvals for clinical trials of MyMD’s pharmaceutical candidates; the timing and results of MyMD’s planned clinical trials for its pharmaceutical candidates; the amount of funds MyMD requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which MyMD operates; MyMD’s ability to retain and attract senior management and other key employees; MyMD’s ability to quickly and effectively respond to new technological developments; MyMD’s ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on MyMD’s proprietary rights; and the impact of the ongoing COVID-19 pandemic on MyMD’s results of operations, business plan and the global economy. A discussion of these and other factors with respect to MyMD is set forth in the Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021, filed by MyMD on November 12, 2021 (as amended on November 15, 2021). Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005631/en/
Contacts
Robert Schatz
(646) 421-9523
rschatz@mymd.com
www.mymd.com
Related Quotes
WRTV News at Noon | March 23, 2022
Top stories from today's Montana This Morning, Thursday, March 24, 2022
The marijuana industry REIT made a notable change to its dividend policy, but so far, that hasn't changed the payout's long-term upward trend.
To be perfectly honest, few traders are revved up about AT&T stock, and for good reason. "The only redeeming quality of owning T has been the heady dividend yield," wrote Real Money Columnist Brad Ginesin recently. AT&T is set to split off Warner Bros to Discovery shareholders, which is likely to occur in mid-April.
NIO's (NIO) stock is trading slightly lower ahead of the Chinese electric-vehicle company's quarterly results due after the closing bell on Thursday.
The FAANG grouping of stocks has been so 2021. Facebook parent Meta Platforms (FB) Amazon.com (AMZN) Apple (AAPL) Netflix (NFLX) and Google parent Alphabet (GOOGL) have struggled this year, thanks to rising interest rates, and in the case of Facebook and Netflix, softer demand.
Hertz has added Tesla’s Model Y crossover to its EV rentals.
He cites a strong economy, low unemployment, rising wages and the beginning of Fed interest rate increases.
Investors may be anticipating a positive review by the FDA of the company's lead drug candidate.
Nvidia Corp.'s pursuit of what it sees as a $1 trillion opportunity won praise from analysts following the company's investor-day presentation, even though the chipmaker's stock conveyed a more muted reaction.
(Bloomberg) — Against all odds and despite sanctions, Russian tycoons are regaining some of their wealth.Most Read from BloombergPutin Adviser Chubais Quits Over Ukraine War, Leaves RussiaChina Plane Crash Update: Report Second Black Box Found ‘Untrue’Russia Central Banker Wanted Out Over Ukraine, Putin Said NoNATO Boosts Forces in East Amid Chemical Incidents WarningWall Street Is Scrambling For the Exits in Moscow — and Billions Are at StakeAfter almost one month of suspension, shares in Mosc
PayPal is the largest digital platform that provides money transfer services. The fast-growing company remains one of the high-profile stocks in today's stock market. But is PayPal stock a buy in the current stock market rally? PayPal boasts a consistent track record of earnings and sales growth, stretching back to at least 2010.
Chinese electric-vehicle maker Nio Inc. late Thursday reported quarterly sales slightly above Wall Street expectations, vowing to make 2022 a year of "reacceleration" for its business and to sell its EVs in more countries.
EV stocks have multiplied in Tesla’s wake and as electric cars look to go mainstream. Here are the top-rated electric vehicle makers.
(Bloomberg) — Activist investor Ryan Cohen is nearing a settlement at Bed Bath & Beyond Inc. that would see three new directors appointed to the retailer’s board, according to people familiar with the matter.Most Read from BloombergPutin Adviser Chubais Quits Over Ukraine War, Leaves RussiaChina Plane Crash Update: Report Second Black Box Found ‘Untrue’Russia Central Banker Wanted Out Over Ukraine, Putin Said NoNATO Boosts Forces in East Amid Chemical Incidents WarningWall Street Is Scrambling
In addition to the electric vehicle manufacturer Tesla, the billionaire runs many companies at the same time, including SpaceX and Neuralink.
Seven in eight workers to pay more tax before next election Rishi Sunak holds back £32bn war chest amid economic uncertainty FTSE 100 edges 0.1pc higher; Pound falls against dollar Ben Marlow: Time to boycott Western companies still operating in Russia Sign up here for our daily business briefing newsletter
Mighty Amazon (NASDAQ: AMZN) wasn't energetic enough to keep pace with the stock market on Thursday. Yes, Amazon will be challenged with higher costs, especially if the recent price increases prove "sticky."
Bitcoin (BTC) is rising alongside a 6% rally in dogecoin (DOGE). Meme stocks are also outperforming in equity markets, reflecting improved appetite for risk among investors. DeFi tokens are lagging, but could catch up with broader upswings in price.
Fidelity's Edward Johnson was instrumental in shaping the asset-management industry and allowing Main Street investors to participate in the stock market like institutional investors.